B. Djavan, M. Remzi, A. Zlotta, V. Ravery, P. Hammerer, A. Reissigl, P. Dobronski, A. Kaisary and M. Marberger, “Complexed Prostate-Specific Antigen, Complexed Prostate-Specific Antigen Density of Total and Transition Zone, Complexed/Total Prostate-Specific Antigen Ratio, Free-to-Total Prostate-Specific Antigen Ratio, Density of Total and Transition Zone Prostate-Specific Antigen: Results of the Prospective Multicenter European Trial,” Urology, Vol. 60, No. 4, 2002, pp. 4-9. doi:10.1016/S0090-4295(02)01

has been cited by the following article:

• TITLE: Correlation of PSA Density to Prostate Cancer Based on Prostate Volume by 3.0 T MRI

  AUTHORS: Rulon L. Hardman, Yuanyuan Liang, Steve Ware, Adam J. Jung, Qi Peng, Fadi El-Merhi, Yumin Chen, Ian M. Thompson

  KEYWORDS: Magnetic Resonance Imaging, Prostatic Neoplasm, Prostate-Specific Antigen

  JOURNAL NAME: Open Journal of Urology, Vol.1 No.3, August 9, 2011

  ABSTRACT: Purpose: Prostate specific antigen levels can be normalized by the prostate volume to give a prostate specific antigen density (PSAd). Magnetic resonance imaging (MRI) can more accurately determine prostate zonal anatomy and prostate volumes compared to transrectal ultrasound, and hence may lead to more accurate PSAd measurements. Methods: Imaging and pathology of men undergoing prostate MRI from April 2007 to May 2009 were reviewed in this retrospective study. 73 patients were included for analysis, of which 45 had prostate cancer and 28 did not have cancer. Total, transitional zone, and peripheral zone values were determined by ultrasound prolate ellipse, MRI prolate ellipse, and MRI segmentation methods. Results: The study population showed an average PSA of 6.3 ng/mL, with the control mean PSA (8.8 ng/mL) being greater than the cancer group (5.3 ng/mL). Transrectal ultrasound underestimated the prostate volume (mean 27.7 mL versus MRI volume of 38.3 mL, p ≤ 0.001). No difference was seen between cancer and control populations using PSAd. PSAd correctly categorized low (Gleason